The income for ten months is 2.3 times that of the whole of last year ᅠ.
In the first ten months of the fiscal year, Dana Pharmaceuticals recorded a revenue margin of 14.6. This figure is 188% higher than the corresponding period and about 2.3 of last year's total income. The average monthly income increased from 645 billion tomans in the first season to 1.6 billion in the second season and 2 billion in the third season. The last season started with about 1.8 meters in a hurry and remained at the high level of the last months. The volume of sales grew by 6% and most of the growth was due to the price. The average sales rate increased 2.7 times. After the good nine-month report, the company also posted a strong monthly report. However, the stock has been sold for the fourth day in a row.
ᅠ value investment ᅠ.